Business
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing
About this update from Longeveron Inc.
[{"type":"text","content":"MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (\"Longeveron\" or the \"Company\"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults. As a life-threatening geriatric condition, aging frailty affects up to 15% of Americans over the age of 65, or 8.1 million individuals, and manifests as a loss of muscle and decreased strength, slowed walking, low activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue. “There is increasing recognition of the unmet medical need in treating and preventing frailty in older adults, and we feel the acceptance of our trial design and rationale for publication in this prestigious, peer-reviewed journal reflects the urgency to develop potential new therapies,” said Geoff Green, CEO of Longeveron. The publication by Longeveron Senior Scientist Dr. Anthony Oliva and colleagues is titled “The Design and Rationale of a Phase 2b, Randomized, Double-Blinded, and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B in Older Adults with Frailty,” and is accessible here (https://link.springer.com/article/10.14283/jfa.2022.2) This trial was designed and conducted in partnership with the National Institute on Aging. The results of the trial were previously announced by the Company on August 13th, 2021. About Aging Frailty Aging Frailty is a life-threatening geriatric condition, which studies have estimated affect approximately 15% of Americans over the age of 65, or 8.1 million individuals. Aging Frailty patients are vulnerable to poor clinical outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics, and therefore it is considered an extreme form of unsuccessful aging. Clinically, frailty manifests as a combination of symptoms that includes loss of muscle and decreased strength, slowed walking, low activity and energy levels, poor end...